Cyclopharm Limited · ASX:CYC
Cyclopharm — Investor Presentation (October 2015)
27 slides from Cyclopharm's investor presentation, Oct 7, 2015
Slide 1: Cyclopharm Limited Investor Presentation
For personal use only Cyclopharm Limited Building a profitable and growing market leader in nuclear medical imaging Investor Presentation James McBrayer, CEO 7 October2015
Slide 2: Contents
Contents For personal use only • 10 Fast Facts • Vision and company description • Company History • Cyclopharm’s market leading products • Growth opportunities and KPI’s • Summary and Outlook • Appendix: FY 2014 & H1 2015 Financial Results
Slide 3: CYC's 10 Fast Facts
CYC’s 10 FAST FACTS For personal use only 1. Technegas is a well established proprietary world leader in functional lung ventilation imaging technology with major revenues generated by single patient consumables 2. Partnering with DraxImage to leverage significant growth opportunities in the USA for
Slide 4: Vision and strategy
Vision and strategy For personal use only • CYC has clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market by expanding the use of our proprietary products and introduce new innovative technology. • Leverage core strengths and well developed experti
Slide 5: Our History
Our History For personal use only 1984 1992 2000 2001 2007 2013 Technegas European Vita Life USFDA Technegas Ultralute discovered & markets Sciences program Plus technology commercialisation established acquires initiated for generator established and trading as Tetley Tetley Technegas launched comm
Slide 6: Cyclopharm Our Business
Cyclopharm Our Business For personal use only Manufacturer and • Continues to generate growing distributor of functional lung revenue, profits and cash flows ventilation imaging drugs and • Trials underway to extend usage equipment to COPD treatment & monitoring (Technegas) • FDA trials progressing
Slide 7: Technegas: Expanding the global footprint
Technegas Expanding the global footprint For personal use only • Technegas sold in 55 countries Technegas Sales Revenue by Region − In 2014 Canada became largest single market for Asia Technegas overtaking France Pacific 19% • Over 3,500,000 patient studies since 1986 Europe & Other North • 1,350 Te
Slide 8: Technegas
Technegas For personal use only ü More accurate and sensitive imaging agent primarily used in Pulmonary Embolism ü Three parts to the technology: generator, aerosol tubing (Patient Administration Set / “PAS”) and crucible(creates nanoparticles) ü PAS is a consumable used in every Technegas procedure
Slide 9: Nuclear imaging: Technegas' superior performance
Nuclear imaging: Technegas’ superior performance For personal use only Technegas advantages • Over 3.5m patient studies without a single adverse patient event • A superior alternative to CTPA (angiograms) in nuclear medicine imaging • Better clinical results at a fraction of the high radiation does
Slide 10: Technegas Overview: Agency vs Distributor Models
TECHNEGAS OVERVIEW Agency vs Distributor Models For personal use only • The majority of Technegas sales are generated through Distributors • Technegas is distributed directly in Australia, New Zealand, Canada and Germany • Distributors allow for low cost market entry at the compromise of full market
Slide 11: Technegas Clinical Trial Program Overview
Technegas – Clinical Trial Program Overview For personal use only USA – Region Expansion Global – Indication Expansion Targeting existing Pulmonary Targeting Chronic Obstructive Embolism (PE) market Pulmonary Disease (COPD) market Structural ventilation study comparing Xe133 vs. Evaluating the effec
Slide 12: USA Existing Market Potential & Licensing Agreement with DraxImage
USA Existing Market Potential & For personal use only Licensing Agreement with DraxImage USA Target Market 4.0 m • DraxImage is the USA market leader in nuclear medicine Pulmonary lung imaging radiopharmaceuticals Embolism (PE) Patient Studies • By teaming with DraxImage more resources can be p.a. i
Slide 13: Technegas Indication Expansion – COPD
Technegas Indication Expansion – COPD For personal use only • The Global incidence of Chronic Obstructive Pulmonary Disease (COPD) is 30x greater than that of Pulmonary Embolism (PE) • It is estimated that by 2020, C.O.P.D. will be the 4th highest cause of death globally. By 2030 COPD will be the 3r
Slide 14: Ultralute Product Overview
UltraluteTM For personal use only Product Overview: • Cyclopharm patented technology • Extends the effective life of Mo-99 generator up to 50% • Each cartridge consumable designed for a maximum of 10 uses • Patents secured in 2014 • Will be designated as laboratory equipment • Market introduction re
Slide 15: Ultralute Generational Overview
ULTRALUTE Generational Overview For personal use only • Designed for the end user application GEN 1 • Ready for launch Q4 2015 with revenues commencing early 2016 • Designed for radiopharmacy application GEN 2 • Development will commence in 2015 for 2017 launch • Designed for n,Gamma reactions • Ult
Slide 16: Macquarie Medical Imaging
Macquarie Medical Imaging For personal use only PET • Joint venture with: X-Ray • 50% Alfred Health Solutions • 30% Macquarie University CT • 20% Cyclopharm • Comprehensive suite of imaging modalities Cardiac CT • State of the art research platform • Growth and profitability linked to ramp-up MRI of
Slide 17: Growth Opportunities and Key Performance Indicators: Technegas
Growth Opportunities and For personal use only Key Performance Indicators Technegas Currency < 15% of revenues are $AUD related; Currently > 60 % of Technegas revenues linked to Euro. Seasonality Historically 2H revenues are stronger due to higher procedures volume during northern hemisphere winters
Slide 18: Growth Opportunities and KPIs: Ultralute, MMI
Growth Opportunities and For personal use only Key Performance Indicators Ultralute Market Europe targeted as the primary market to launch due to the highest concentration of end user Mo99 generators in Penetration the world 1st Generation targeted for launch in Germany at the EANM in October with i
Slide 19: 2015 & Outlook
2015 & Outlook For personal use only Solid growth prospects and healthy capital position ü Leveraging off record financial results in 2014 ü Softer Year on Year 2015 1H results due to timing differences in purchases ü Underlying profitability expected to continue with stronger 2H 2015 confirmed with
Slide 20: Disclaimer
Disclaimer For personal use only Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of
Slide 21: Appendix Section
For personal use only APPENDIX SECTION 21
Slide 22: FY14 Financial Highlights
FY14 Financial Highlights For personal use only ü Record sales of $12.1 million ü Record Technegas division operating EBITDA of $2.2 million ü Record NPAT of $4.1 million (vs 2013 loss of $10.1m), includes: § Technegas division NPAT: $2.4 million; and § Net litigation proceeds of $2.2 million ü Tech
Slide 23: FY14 Operating Highlights
FY14 Operating Highlights For personal use only ü Technegas’ sales revenue grew in all major markets § Sales of Technegas Generators & Patient Administration Sets up 10% on pcp § Canada now represents our no.1 market ü Commenced Technegas COPD trials in China ü Progress in obtaining FDA approval for
Slide 24: FY14 Group Profit & Loss
FY14 Group Profit & Loss For personal use only Record Sales and Profit Year ended 31 December ($000’s) 2014 2013 • Technegas continues to perform Underlying Results1: strongly Revenue 12,047 11,882 • Price increases and lower A$ drove improved gross margins Technegas EBITDA (Excludes FDA costs) 2,63
Slide 25: Technegas – FY14 Performance
Technegas – FY14 Performance For personal use only Record financial result Year ended 31 December ($000’s) 2014 2013 Change • Technegas recorded a record Technegas Results1: financial result in FY14 Sales Revenue • PAS margins enhanced by PAS 9,384 8,583 ↑ 9.3% improved local prices in Asia and Gene
Slide 26: H1 2015 Group Profit & Loss
H1 2015 Group Profit & Loss For personal use only Continued Solid Sales and Profits • Technegas continues to perform Half Year ended 30 June ($000’s) H1 2015 H1 2014 strongly Underlying Results1: • Price increases and lower A$ Reported Revenue 5,078 6,554 drove improved gross margins Technegas PBT (
Slide 27: H1 2015 Group Balance Sheet
H1 2015 Group Balance Sheet For personal use only Balance Sheet Strong with Major Debt Retired • Improved cash position Balance as at ($000’s) 30/6/2015 31/12/2014 driven by strong cash flows from Cash 3,613 3,268 operations Other current assets 5,392 5,582 • Net proceeds from Cyclopet Non-current A